Publications by authors named "D E Adelberg"
Background: Results from the phase III KEYNOTE-177 study established pembrolizumab as a new first-line standard of care for microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Previous results from KEYNOTE-177 showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with pembrolizumab versus chemotherapy ± bevacizumab/cetuximab in MSI-H/dMMR mCRC. Results after >5 years of follow-up are reported.
View Article and Find Full Text PDFArticle Synopsis
- * In this phase III trial, 480 eligible patients were randomly assigned to receive either the combination therapy or standard care options, with the primary focus on overall survival (OS).
- * The results showed that the combination did not significantly improve median OS compared to standard care (9.8 months vs. 9.3 months), and although more patients on the combination experienced severe adverse events, there were no new safety issues identified.
Background: The phase 1b KEYNOTE-651 study evaluated pembrolizumab plus chemotherapy in microsatellite stable or mismatch repair-proficient metastatic colorectal cancer.
Patients And Methods: Patients with microsatellite stable or mismatch repair-proficient metastatic colorectal cancer received pembrolizumab 200 mg every 3 weeks plus 5-fluorouracil, leucovorin, oxaliplatin (previously untreated; cohort B) or 5-fluorouracil, leucovorin, irinotecan (previously treated with fluoropyrimidine plus oxaliplatin; cohort D) every 2 weeks. Primary end point was safety; investigator-assessed objective response rate per RECIST v1.
Background: The randomized, open-label, phase III LYNK-003 study assessed the efficacy of first-line maintenance olaparib, alone or in combination with bevacizumab, versus bevacizumab plus a fluoropyrimidine in participants with unresectable or metastatic colorectal cancer (mCRC). We present results of the prespecified interim futility analysis.
Methods: Eligible participants were ≥18 years of age with unresectable or mCRC that had not progressed after induction with first-line bevacizumab plus 5-fluorouracil plus oxaliplatin plus leucovorin (FOLFOX) or capecitabine plus oxaliplatin (CAPOX).
Article Synopsis
- - The KEYNOTE-651 study assessed the combination of pembrolizumab and binimetinib, with or without chemotherapy, in patients with metastatic colorectal cancer that was microsatellite stable/mismatch repair-proficient.
- - Cohorts showed varying levels of dose-limiting toxicities (DLTs), with the most significant occurring in cohort C at 33%, leading to a halt in dose escalation for that group and a dose reduction in cohort E.
- - Overall, the study found binimetinib combined with pembrolizumab was tolerable in cohort A, but the objective response rates were low across all cohorts, with no significant additional benefit from adding binimetinib to pembrolizumab.